Anteris Technologies Ltd
ASX:AVR
Intrinsic Value
Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. [ Read More ]
The intrinsic value of one AVR stock under the Base Case scenario is 1.16 AUD. Compared to the current market price of 21 AUD, Anteris Technologies Ltd is Overvalued by 94%.
Valuation Backtest
Anteris Technologies Ltd
Run backtest to discover the historical profit from buying and selling AVR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Anteris Technologies Ltd
Current Assets | 35.9m |
Cash & Short-Term Investments | 30.8m |
Receivables | 1.3m |
Other Current Assets | 3.8m |
Non-Current Assets | 9.8m |
PP&E | 7.8m |
Intangibles | 1.4m |
Other Non-Current Assets | 610k |
Current Liabilities | 13.8m |
Accounts Payable | 10.6m |
Other Current Liabilities | 3.2m |
Non-Current Liabilities | 3.3m |
Long-Term Debt | 1.5m |
Other Non-Current Liabilities | 1.7m |
Earnings Waterfall
Anteris Technologies Ltd
Revenue
|
7m
AUD
|
Cost of Revenue
|
-1.6m
AUD
|
Gross Profit
|
5.4m
AUD
|
Operating Expenses
|
-73.2m
AUD
|
Operating Income
|
-67.7m
AUD
|
Other Expenses
|
382.9k
AUD
|
Net Income
|
-67.3m
AUD
|
Free Cash Flow Analysis
Anteris Technologies Ltd
AVR Profitability Score
Profitability Due Diligence
Anteris Technologies Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Anteris Technologies Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
AVR Solvency Score
Solvency Due Diligence
Anteris Technologies Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Anteris Technologies Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVR Price Targets Summary
Anteris Technologies Ltd
According to Wall Street analysts, the average 1-year price target for AVR is 30.6 AUD with a low forecast of 30.3 AUD and a high forecast of 31.5 AUD.
Shareholder Return
AVR Price
Anteris Technologies Ltd
Average Annual Return | 87.29% |
Standard Deviation of Annual Returns | 133.43% |
Max Drawdown | -75% |
Market Capitalization | 374.2m AUD |
Shares Outstanding | 18 095 300 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.
Contact
IPO
Employees
Officers
The intrinsic value of one AVR stock under the Base Case scenario is 1.16 AUD.
Compared to the current market price of 21 AUD, Anteris Technologies Ltd is Overvalued by 94%.